Research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR - Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a "sell" rating on the stock.
InspireMD Price Performance
NYSE NSPR traded down $0.02 during mid-day trading on Monday, hitting $2.58. The stock had a trading volume of 16,587 shares, compared to its average volume of 52,876. The firm's 50 day moving average is $2.66 and its 200 day moving average is $2.74. The stock has a market capitalization of $79.04 million, a price-to-earnings ratio of -3.44 and a beta of 0.62. InspireMD has a twelve month low of $2.07 and a twelve month high of $3.80.
Hedge Funds Weigh In On InspireMD
A number of institutional investors and hedge funds have recently bought and sold shares of NSPR. XTX Topco Ltd purchased a new position in InspireMD in the 1st quarter worth approximately $38,000. Brown Advisory Inc. purchased a new position in InspireMD during the first quarter worth approximately $27,000. Huntleigh Advisors Inc. acquired a new position in InspireMD during the first quarter worth $316,000. Uniting Wealth Partners LLC purchased a new stake in InspireMD in the 1st quarter valued at $27,000. Finally, Courier Capital LLC acquired a new stake in shares of InspireMD in the 1st quarter worth $81,000. 44.78% of the stock is currently owned by institutional investors and hedge funds.
About InspireMD
(
Get Free Report)
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
See Also
Before you consider InspireMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InspireMD wasn't on the list.
While InspireMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
